Cargando…
Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
Leiomyosarcoma (LMS) is characterized by high genomic complexity, and to date, no specific targeted therapy is available. In a genome-wide approach, we profiled genomic aberrations in a small cohort of eight primary tumours, two relapses, and eight metastases across nine different patients. We ident...
Autores principales: | Böhm, Michael J., Marienfeld, Ralf, Jäger, Daniela, Mellert, Kevin, von Witzleben, Adrian, Brüderlein, Silke, Wittau, Mathias, von Baer, Alexandra, Schultheiss, Markus, Mayer-Steinacker, Regine, Rücker, Frank G., Möller, Peter, Bullinger, Lars, Barth, Thomas F. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360577/ https://www.ncbi.nlm.nih.gov/pubmed/30804704 http://dx.doi.org/10.1155/2019/3914232 |
Ejemplares similares
-
HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas
por: Jäger, Daniela, et al.
Publicado: (2017) -
Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway
por: Lübbehüsen, Christoph, et al.
Publicado: (2019) -
Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation
por: Hasenfratz, Marc, et al.
Publicado: (2021) -
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020) -
Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)